{
    "id": "0297a568-6dca-efb2-e5cb-2cd21891ef3e",
    "indications": {
        "text": "tigecycline injection tetracycline class antibacterial indicated patients 18 years age older : complicated skin skin structure infections ( 1.1 ) complicated intra-abdominal infections ( 1.2 ) community-acquired bacterial pneumonia ( 1.3 ) limitations : tigecycline injection indicated treatment diabetic foot infection hospital-acquired pneumonia , including ventilator-associated pneumonia ( 1.4 ) . reduce development drug-resistant bacteria maintain effectiveness tigecycline injection antibacterial drugs , tigecycline injection used treat infections proven strongly suspected caused bacteria ( 1.5 ) .",
        "doid_entities": [
            {
                "text": "bacterial pneumonia (DOID:874)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_874"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial dose 100 mg , followed 50 mg every 12 hours administered intravenously approximately 30 60 minutes . ( 2.1 ) severe hepatic impairment ( child pugh c ) : initial dose 100 mg followed 25 mg every 12 hours . ( 2.2 ) obtain baseline blood coagulation parameters , including fibrinogen , continue monitor regularly treatment tigecyclineetracycline . ( 2.4 , 5.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "tigecycline injection , usp supplied single-dose 5 ml glass vial , containing 50 mg tigecycline , usp lyophilized powder reconstitution . supplied : 10 single-dose vials one box . ndc 60505-6098-1 prior reconstitution , tigecycline injection , usp stored 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature . ] reconstituted solution tigecycline injection , usp may stored room temperature ( exceed 25\u00b0c/77\u00b0f ) 24 hours ( 6 hours vial remaining time intravenous bag ) [ ( 2.5 ) ] .",
    "adverseReactions": "tigecycline injection contraindicated patients known hypersensitivity tigecycline excipients . included anaphylactic [ ( 5.3 ) ( 6.2 ) ] .",
    "ingredients": [
        {
            "name": "TIGECYCLINE",
            "code": "70JE2N95KR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_149836"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "organization": "Apotex Corp",
    "name": "Tigecycline",
    "effectiveTime": "20250501",
    "indications_original": "Tigecycline for injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use: Tigecycline for injection\u00a0is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.5 ).",
    "contraindications_original": "Initial dose of 100 mg, followed by 50 mg every 12 hours administered intravenously over approximately 30 to 60 minutes. (2.1) Severe hepatic impairment (Child Pugh C): Initial dose of 100 mg followed by 25 mg every 12 hours. ( 2.2 ) Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecyclineetracycline. ( 2.4 , 5.6 )",
    "warningsAndPrecautions_original": "Tigecycline for injection, USP is supplied in a single-dose 5 mL glass vial, each containing 50 mg tigecycline, USP lyophilized powder for reconstitution. \n                  Supplied: \n                  10 single-dose vials in one box. NDC 60505-6098-1\n                  Prior to reconstitution, tigecycline for injection, USP should be stored at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP Controlled Room Temperature.] The reconstituted solution of tigecycline for injection, USP\u00a0may be stored at room temperature (not to exceed 25\u00b0C/77\u00b0F) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag) [see Dosage and Administration (2.5)].",
    "adverseReactions_original": "Tigecycline for injection is contraindicated for use in patients who have known hypersensitivity to tigecycline or to any of the excipients. Reactions have included anaphylactic reactions [\n                     see Warnings and Precautions (5.3) and Adverse Reactions (6.2)\n                     ].",
    "drug": [
        {
            "name": "Tigecycline",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_149836"
        }
    ]
}